Nuclear receptors have long been a focus in cancer research. The role of dysregulated nuclear receptor mediated signaling pathways in tumorigenesis has been well documented in a variety of cancers. This makes nuclear receptors important therapeutic targets for identifying new therapies to combat cancer.
In this webinar, learn about cutting edge research from distinguished professors from Penn State University as they talk about the role of specific nuclear receptors in cancer, including:
- Aryl Hydrocarbon Receptor (AhR)
- Farnesoid X Receptor (FXR)
- Peroxisome Proliferator-Activated Receptors (PPARα, PPARδ and PPARγ)
Register to hear the featured panelists discuss the function of specific receptors, their mechanisms in various types of cancer and what makes them good therapeutic targets for cancer drug discovery research.
Jack Vanden Heuvel, PhD; Professor of Molecular Toxicology, Pharmacology & Toxicology Undergraduate Program Coordinator, Penn State University; Chief Scientific Officer, INDIGO Biosciences
Dr. Vanden Heuvel is a recognized expert in the field of nuclear receptor biology and toxicology with over 100 peer-reviewed publications. In addition to his role as CSO at INDIGO, Dr. Vanden Heuvel is a Professor at Penn State University where he is Program Coordinator of the undergraduate Toxicology Program, Co-Director of the Center of Excellence in Nutrigenomics and leads an extramurally funded research program.Message Presenter
Andrew D. Patterson, PhD; John T. and Paige S. Smith Professorship, Professor of Molecular Toxicology, Professor of Biochemistry & Molecular Biology, Penn State University
Dr. Patterson is the Smith Professor and Professor of Molecular Toxicology at the Pennsylvania State University, University Park, PA and is the Scientific Director of Metabolomics. He holds joint appointments in the department of veterinary and biomedical sciences and the department of biochemistry and molecular biology. He and his students, postdocs and collaborators focus on understanding the host-metabolite-microbiota communication network — specifically how the manipulation of gut microbiota by diet and/or xenobiotics impacts host metabolites, their metabolism and how these co-metabolites interact with host ligand-activated transcription factors. The lab employs a variety of tools, including NMR- and mass spectrometry-based metabolomics, genomics and conventional and gnotobiotic transgenic mice, to facilitate its study of these pathways and understand their impact on human health and disease.Message Presenter
Gary H. Perdew, PhD; H. Thomas and Dorothy Willits Hallowell Chair in Agricultural Sciences, Penn State University
Dr. Perdew is the H. Thomas & Dorothy Willits Hallowell Chair and Professor of Veterinary and Biomedical Sciences in the College of Agricultural Sciences at Penn State University. He is also the Director of the Center for Molecular Toxicology and Carcinogenesis. Dr. Perdew studies how the aryl hydrocarbon receptor (AhR) pathway interacts with the microbiome, the immune system and protective barriers in skin and the gut. His team was the first to identify the protein subunit composition of the AhR and has made major contributions in the comparison of the human and mouse AHR and the evolution of the AHR in primates. He has over 100 publications that have been cited thousands of times, and in 2017, Dr. Perdew received a NIEHS Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) Outstanding Investigator Award for his integrative research and leadership in the field.Message Presenter
Jeffrey M. Peters, PhD; Distinguished Professor of Molecular Toxicology & Carcinogenesis, Deputy Director, The Penn State Cancer Institute
Dr. Peters is a Distinguished Professor of Molecular Toxicology and Carcinogenesis at Penn State University, and the Deputy Director of the Penn State Cancer Institute. Dr. Peters has performed seminal research focused on the biological role of the peroxisome proliferator-activated receptors (PPARs) with particular interest in PPARβ/δ. Studies from his group have shown that the hepatocarcinogenic effect of PPARα agonists requires a functional PPARα. His more recent research is focused on elucidating functional roles of PPARβ/δ in disease, with particular interest in epithelial cancers.Message Presenter
K. Sandeep Prabhu, PhD; Head of the Department of Veterinary and Biomedical Sciences, Professor of Immunology and Molecular Toxicology, Penn State University
Dr. Prabhu is the Head of the Department of Veterinary and Biomedical Sciences and Professor of Immunology and Molecular Toxicology at Penn State University. The research conducted in Dr. Prabhu’s laboratory focuses on various cellular and molecular mechanisms by which micronutrients such as selenium and other products of natural origin alter the host response and immune function in response to oxidative stress caused by environmental toxicants and pathogens. Current research includes work into bioactive compounds of natural origin as anti-inflammatory and anti-carcinogenic agents, isolation and characterization of endogenous ligands for the peroxisome proliferator-activated receptors (PPARs) and the anti-inflammatory effects of selenium.Message Presenter
Who Should Attend?
Researchers, Staff Scientists, Directors and VPs of R&D and Lab Managers focused on:
- Cancer Research
- Precision Medicine
- Drug Discovery
- Safety Pharmacology
- In vitro Toxicology
What You Will Learn
- Learn about mechanisms of nuclear receptors in various types of cancers
- Understand specific receptors and why they are therapeutic targets for cancer drug discovery
- Gain insight into nuclear receptors and the human relevance of animal models
INDIGO Biosciences, Inc
INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. We supplement the world’s largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms, aim to reduce the time, cost, and risk associated with the discovery process.